Harry studied an integrated Master’s degree in biology at Durham University before joining Cancer Research UK in November 2018. He recently completed a Master’s in science communication at Imperial College London part-time alongside his work in communications teams across the charity. He currently sits in Cancer Research UK’s digital news team, writing news and analysis articles for their news site as well as information about their funded research for their website.
A blood test capable of catching any cancer at an early stage before any symptoms may sound like science fiction but just how close are researchers to making it a reality?
We talk to Professor Sir Michael Marmot, who’s been at the forefront of health inequality research for decades, to discuss what it is and how we can reduce it.
3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.
A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).
The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.
More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.
People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.